Follow us for updates
© 2020 reportr.world
Read the Story →

Philippines to Start WHO Vaccine Trials in January

'Our safest bets.'
by Ara Eugenio
Dec 7, 2020
Photo/s: National Cancer Institute via Unsplash
Shares

The Philippines will start testing in January COVID-19 vaccines under the World Health Organization's Solidarity Trials, which is expected to be a much faster process, a scientist leading the country's search for a vaccine said Monday.

At least 4,000 Filipinos are expected to participate in the WHO trials, said microbiologist and immunologist Nina Gloriani who leads DOST's vaccine expert panel.

MORE ON VACCINE TRIALS: 

What are Vaccine Trials and How Do They Work?

Explained: COVID-19 Vaccine Trials in the Philippines

President Rodrigo Duterte issued last week an Executive Order authorizing the Food and Drug Adminsitration to grant "emergency use" of COVID-19 vaccines and drug candidates approved by their origin country's regulatory boards. 

Gloriano told TeleRadyo that the vaccines under the WHO trials are "our safest bet". 

"Mas mabuti na may clinical trial kasi iba-iba responses ng mga tao sa vaccine depende sa ethnicity," she said. The WHO is eyeing five candidate vaccines but only two of which will be named this week. 

Continue reading below ↓

Initial observations of the trial participants could last three to six months, after which they could apply for emergency use if deemed effective. The observation period could last up to two years to note all possible side effects.

Initial participants for the trials have been identified already and will come from communities in Metro Manila, Cebu, and Davao, which are locations with high incidence of COVID-19. 

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to reportr.world newsletter, you agree to our Terms of Service and Privacy Policy.